Financial Survey: MannKind Corporation (MNKD) vs. The Competition

MannKind Corporation (NASDAQ: MNKD) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare MannKind Corporation to similar companies based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, earnings and risk.


This table compares MannKind Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MannKind Corporation -155.83% -24.93% -130.34%
MannKind Corporation Competitors -5,182.24% -428.32% -40.70%

Volatility & Risk

MannKind Corporation has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. Comparatively, MannKind Corporation’s peers have a beta of 0.99, meaning that their average stock price is 1% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MannKind Corporation and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind Corporation 2 1 1 0 1.75
MannKind Corporation Competitors 793 3135 11398 229 2.71

MannKind Corporation presently has a consensus price target of $0.92, suggesting a potential downside of 71.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.63%. Given MannKind Corporation’s peers stronger consensus rating and higher probable upside, analysts plainly believe MannKind Corporation has less favorable growth aspects than its peers.

Insider & Institutional Ownership

14.0% of MannKind Corporation shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 1.6% of MannKind Corporation shares are held by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares MannKind Corporation and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
MannKind Corporation $174.76 million $125.66 million -11.89
MannKind Corporation Competitors $290.00 million $35.57 million 150.30

MannKind Corporation’s peers have higher revenue, but lower earnings than MannKind Corporation. MannKind Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


MannKind Corporation peers beat MannKind Corporation on 8 of the 12 factors compared.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with's FREE daily email newsletter.

Leave a Reply